Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday. A number of other research analysts also recently commented on the company. Mizuho reduced their price target on Corbus Pharmaceuticals from $44.00 […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday. Several other equities research analysts have also recently weighed in on the stock. Oppenheimer increased their price target on shares of ACADIA Pharmaceuticals […]

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) had its target price lowered by analysts at HC Wainwright from $30.00 to $27.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 94.38% from the stock’s current price. A […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Sunday. Several other equities analysts have also issued reports on ALNY. JPMorgan Chase & Co. lowered their target price on shares of Alnylam […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price objective cut by stock analysts at Royal Bank Of Canada from $445.00 to $350.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential […]